Rukiye Nazan Eraslan

Dr. Eraslan rejoined the GBG team in 2019. As the Managing Director of Invivotek, she leads a cross-functional team of scientists who conduct pre-clinical studies that enable interrogation of immunotoxicity, mechanisms of action, and diagnostic hypotheses and ensures target engagement and pathway analysis activities to support target identification and immunotherapy in autoimmune diseases and oncology. She leads the scientific negotiation and due diligence as a first layer to deliver decisional statements and explain data-driven scientific rationale into the business. Rukiye also provides program/project management and operational support for drug development programs/projects (DDPP) to maintain accurate plans and documentation.

Dr. Eraslan began her career with GBG in 2013 at Invivotek as Team Leader, Immunology/Oncology, a position she held for over 3 years. In February 2019, she returned to the GBG family to become the Managing Director of Invivotek.

Dr. Eraslan received an M.S. in Molecular Biology from the Illinois Institute of Technology in Chicago, IL. She earned a Ph.D. in Immunology at the University of Illinois in Chicago, IL. Dr. Eraslan completed her post-doctoral fellowship in Immunology at Northwestern University Medical School in Chicago, Il.